TopBP1-IN-4
TopBP1-IN-4 is a TopBP1 inhibitor, with an IC50 value of 2.47 to 3.8 nM against the TopBP1 BRCT7/8 domain. TopBP1-IN-4 selectively disrupts BRCT7/8-dependent oncogenic protein-protein interactions, does not interfere with other BRCT domain-mediated functions of TopBP1, and has no effect on DNA replication. TopBP1-IN-4 restores E2F1-mediated Apoptosis in cells. TopBP1-IN-4 induces mitotic catastrophe in cells. TopBP1-IN-4 overcomes Osimertinib (HY-15772) resistance in EGFR-mutant non-small cell lung cancer models. TopBP1-IN-4 can be used in studies related to triple-negative breast cancer, ovarian cancer, non-small cell lung cancer, and acute myeloid leukemia.
For research use only. We do not sell to patients.
- Formula: C26H26Cl2N2O4
- Molecular Weight:501.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-468 | IC50 |
0.15 μM
|
Inhibition of clonogenic survival in MDA-MB-468 triple-negative breast cancer cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in MDA-MB-468 triple-negative breast cancer cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| MDAH 2774 | IC50 |
0.18 μM
|
Inhibition of clonogenic survival in MDAH-2774 ovarian cancer cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in MDAH-2774 ovarian cancer cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| A2780cis | IC50 |
0.46 μM
|
Inhibition of clonogenic survival in cisplatin-resistant A2780cis ovarian cancer cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in cisplatin-resistant A2780cis ovarian cancer cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| A549 | IC50 |
0.5 μM
|
Inhibition of clonogenic survival in A549 lung cancer cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in A549 lung cancer cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| HCC95 | IC50 |
0.54 μM
|
Inhibition of clonogenic survival in HCC95 lung cancer cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in HCC95 lung cancer cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| H1975 | IC50 |
0.32 μM
|
Inhibition of clonogenic survival in EGFR-mutated H1975 NSCLC cells assessed by clonogenic survival assay with crystal violet staining.
Inhibition of clonogenic survival in EGFR-mutated H1975 NSCLC cells assessed by clonogenic survival assay with crystal violet staining.
|
42555732 |
| Kasumi 1 | IC50 |
0.46 μM
|
Reduction of cell viability in Kasumi-1 acute myelogenous leukemia cells incubated for 45 hours by CCK-8 assay using WST-8 solution.
Reduction of cell viability in Kasumi-1 acute myelogenous leukemia cells incubated for 45 hours by CCK-8 assay using WST-8 solution.
|
42555732 |
In Vitro
TopBP1-IN-4 (Compound CS18) (0-0.02 μM) potently inhibits the peptide binding function of TopBP1-BRCT7/8 with an IC50 between 2.47 nM and 3.8 nM in a cell-free in vitro system[1].
TopBP1-IN-4 (0.1-2.5 μM) exhibits strong clonogenic growth inhibitory activity across a broad panel of cancer cell lines, with IC50 values in the sub-micromolar range spanning 0.15 μM to 0.67 μM[1].
TopBP1-IN-4 (3 days) potently suppresses viability of t(8;21) translocation, p53R248Q mutant Kasumi-1 acute myelogenous leukemia cells with an IC50 of 0.46 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Kasumi-1 acute myelogenous leukemia cells
-
Concentration:Titrated across a range of concentrations
-
Incubation Time:3 days
-
Result:Reduced Kasumi-1 cell viability with an IC50 of 0.46 μM.
In Vivo
TopBP1-IN-4 (30 mg/kg; i.p.; 3 times weekly; 17 days) significantly inhibits the growth of Osimertinib (HY-15772)-resistant H1975 NSCLC xenografts in NSG mice with minimal normal tissue toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice[1]
-
Dosage:15 mg/kg (TGI); 30 mg/kg (TGI); 45 mg/kg (TGI); 60 mg/kg (TGI); 40 mg/kg (TGI)
-
Administration:i.p.; 3 times weekly; 3 weeks (15-60 mg/kg); i.p.; twice weekly; 15 days (40 mg/kg)
-
Result:Suppressed TNBC PDX tumor growth at 40 mg/kg twice weekly.
Induced increased PARP1 cleavage in tumor tissue at 40 mg/kg twice weekly.
Increased the thermal stability of TopBP1 in xenograft tumor tissue confirming direct in vivo target engagement at 40 mg/kg twice weekly.
Did not induce apoptosis or alter Ki-67 staining in intestinal crypts at all tested doses.
Showed no significant mouse body weight loss or overt toxicity at all tested doses.
Exhibited dose-dependent in vivo antitumor activity across the 15 to 60 mg/kg three times weekly dose range, with no plateau in efficacy observed at the highest 60 mg/kg dose.
All doses up to 60 mg/kg were well tolerated by mice.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; 3 times weekly; 17 days
-
Result:Reduced H1975-OsiR tumor growth significantly.
Showed no significant changes in mouse body weight at 30 mg/kg three times weekly.
Did not induce alteration of Ki-67 staining or apoptosis in mouse intestinal crypts, indicating no overt intestinal tissue toxicity.
Chemical Information
-
Molecular Weight 501.40
-
Formula C26H26Cl2N2O4
-
SMILES
OC1=C(C2=CC=CC=C2)C=C(OC(C=C3CN4CCN(C5=CC=C(O)C=C5)CC4)=O)C3=C1.Cl.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)